Document Detail


Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.
MedLine Citation:
PMID:  23197038     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
In vitro pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.
Authors:
Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Related Documents :
23266428 - Additive inhibition of human α(1)β(2)γ(2) gaba(a) receptors by mixtures of commonly ...
23568068 - Drugs dispensed at the division of neonatology at university hospital in río cuarto, c...
23434058 - Methotrexate: new therapeutic approaches.
23420518 - Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.
12324478 - Use of on-site testing for drugs of abuse.
22646748 - Quantification of multiple infections of plasmodium falciparum in vitro.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  11     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  909-22     Citation Subset:  IM    
Affiliation:
1] AstraZeneca R&D, Alderley Park, Cheshire SK10 4TG, UK. [2].
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase I trials of targeted anticancer drugs: a need to refocus.
Next Document:  Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.